Navigation Links
Moffitt researchers find cancer therapies affect cognitive functioning among breast cancer survivors
Date:4/20/2012

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida and University of Kentucky have found that breast cancer survivors who have had chemotherapy, radiation or both do not perform as well on some cognitive tests as women who have not had cancer.

They published their study in the April 1 issue of Cancer.

"Survivors of breast cancer are living longer, so there is a need to better understand the long-term effects of cancer therapies, such as chemotherapy and radiation," said study lead author Paul B. Jacobsen, Ph.D., associate center director for Population Sciences.

To carry out their study, the researchers recruited 313 women being treated by either chemotherapy or radiotherapy for early stage breast cancer at Moffitt Cancer Center and the University of Kentucky Chandler Medical Center. Those who had undergone treatment for cancer were tested six months after treatment and then tested again 36 months after having completed treatment.

They also recruited a control group of women who did not have cancer. These participants were also tested at six months and 36 months.

Participants in all groups were within five years of age, and breast cancer patients were matched with noncancer patients who lived in their same ZIP codes. Participants were tested cognitively with respect to processing speed (quick task completion under pressure), executive functioning (ability to shift cognitive sets and solve novel problems), the two domains expected to be most affected by chemotherapy. They were also tested with regard to verbal abilities.

"Our findings were partially consistent with prior research," explained Jacobsen. "We found that chemotherapy-treated patients performed worse than noncancer controls in processing speed, executive functioning and verbal ability. These domains may be the domains most affected by chemotherapy."

The also found test results for the radiotherapy group to be similar to the results of those in the chemotherapy group. Additionally, they discovered that the noncancer group improved in these cognitive abilities over time while the chemotherapy and radiotherapy groups did not. There were no differences in performance between the radiotherapy and chemotherapy groups, noted the researchers.

The researchers commented that they were fortunate for having included the radiotherapy groups because their results were so similar to the chemotherapy group. Had that group not been included, conclusions could have been drawn to suggest that the cognitive differences between the noncancer group and the chemotherapy group were specific to chemotherapy.

"Since patients report cognitive problems that interfere with their daily activities, early workups should include tests to determine cognitive functioning prior to treatment," concluded Jacobsen. "Future research also needs to investigate factors that may affect both chemotherapy patients and those receiving radiotherapy. Providers may wish to communicate that such effects can accompany chemotherapy and radiation therapy."


'/>"/>

Contact: Patty Kim
patty.kim@moffitt.org
813-745-7322
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. New Moffitt Cancer Center patent promises to accelerate cancer trials
2. Moffitt, Sanford-Burnham and Florida Hospital create Personalized Medicine Partnership of Florida
3. Fibroblasts contribute to melanoma tumor growth, say Moffitt Cancer Center researchers
4. Moffitt Cancer Center researchers find potential target for treating metastatic cancer
5. Moffitt researchers will be strong participants in American Society of Hematology meeting
6. Moffitt Cancer Center researchers find MK1775 active against sarcomas
7. Moffitt Cancer Center researchers find men less willing to be screened for cancer
8. Moffitt Cancer Center researchers unravel biochemical factor important in tumor metastasis
9. Moffitt Cancer Center researchers find regulatory T-cell clue to help prevent GVHD
10. Moffitt Cancer Center researchers find more clues to causes of breast cancer
11. Moffitt researchers find possible key to preventing chemotherapy resistance in ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... DESCO ... acquired Pocono Sterilizer, an equipment sterilization service and sales company located in Pennsylvania. ... medical and research-related equipment and asset management services to the medical and academic ...
(Date:5/4/2016)... Santa Clara, California (PRWEB) , ... May 04, ... ... (ICOCD-2016) organized by United Scientific Group is scheduled on July 25-27, 2016 at ... students and other health care professionals from educational institutes and research organizations across ...
(Date:5/3/2016)... Minnesota (PRWEB) , ... May 04, 2016 , ... ... more than 40 national and global construction firms representing the Construction Industry Safety ... have joined forces with one purpose: to inspire everyone in the industry to ...
(Date:5/3/2016)... ... ... ProIntro Glitch is a set of 30 self-animating glitch-themed intros created exclusively ... add a terrifying opener to any video or media. Choose from unique styles with ... contrast, all the user has to do is increase the turn on background animations, ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... its 2016 Champion Award to Charles D. Pulido, R.Ph., Co-Founder of NCPDP and ... M.S., Ph.D., Pharmacy Advisor and Health IT Specialist, Office of the National Coordinator ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... -- Intec Pharma Ltd. (NASDAQ: ... announced the appointment of Pnina Strauss-Levy as ... Strauss-Levy has 15 years of experience in clinical research ... record, having supported the advancement of several products through ... the United States and ...
(Date:5/3/2016)... 3, 2016 Norgine ... sie einen entscheidenden Meilenstein durch diese Veröffentlichung ... zum Handeln, um Patientenresultate  bei Verdauungs- und ... Fortschritten im Verständnis der Hepatischen Enzephalopathie bei ... für Hepatische Enzephalopathie in der Öffentlichkeit zu ...
(Date:5/2/2016)... 2, 2016  Deerfield announced today it led ... Vision, Inc. Graybug Vision is an early stage ... transform care for ocular diseases including wet age-related ... was first developed at Johns Hopkins University and ... Graybug Vision is developing ophthalmology ...
Breaking Medicine Technology: